Skip to main content
Veterinary Medicines

FELIGEN CRP LYOPHILISAT ET SOLVANT POUR SUSPENSION INJECTABLE

Authorised
  • Feline panleucopenia virus, strain LR 72, Live
  • Felid herpesvirus 1, strain F2, Live
  • Feline calicivirus, strain F9, Live

Product identification

Medicine name:
FELIGEN CRP LYOPHILISAT ET SOLVANT POUR SUSPENSION INJECTABLE
Active substance:
  • Feline panleucopenia virus, strain LR 72, Live
  • Felid herpesvirus 1, strain F2, Live
  • Feline calicivirus, strain F9, Live
Target species:
  • Cat
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Feline panleucopenia virus, strain LR 72, Live
    3.70
    log10 cell culture infective dose 50
    /
    1.00
    unit(s)
  • Felid herpesvirus 1, strain F2, Live
    5.00
    log10 cell culture infective dose 50
    /
    1.00
    unit(s)
  • Feline calicivirus, strain F9, Live
    4.60
    log10 cell culture infective dose 50
    /
    1.00
    unit(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AD04
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/9097407 0/1980
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 29/10/2024

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 29/10/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."